Results 261 to 270 of about 2,069,350 (347)
ABSTRACT Background Various drug‐eluting stents (DES) are currently used for percutaneous coronary intervention (PCI). However, long‐term trials reveal inconsistent results in head‐to‐head comparisons. Aims To conduct a network meta‐analysis of relevant trials to assess the performance of different DES currently used in PCI.
Aman Goyal+7 more
wiley +1 more source
Contemporary Perspectives on Chronic Renal Disorders
ABSTRACT The prevalence of renal diseases and its associated burden on healthcare have tremendously risen in the past few years. From simple markers assessing kidney function, current renal research delves into understanding the diseases at the cellular and molecular levels and not just at treating, but at improving quality of life, arresting ...
Deenadhayalan Ashok+5 more
wiley +1 more source
ABSTRACT Background Precise risk prediction of chronic diseases is essential for effective preventive care and management. Machine learning (ML) is a promising avenue to enhance chronic disease risk prediction; however, a comprehensive assessment of ML performance across various chronic diseases, populations, and health settings is needed. Methods This
Ebenezer Afrifa‐Yamoah+4 more
wiley +1 more source
Mediastinal emphysema after long-distance flight with ketoacidosis and underlying diabetes mellitus type 1. [PDF]
Ardila Pardo GL+3 more
europepmc +1 more source
Total Synthesis of (−)‐Vescalagin, the Iconic Member of the C‐Glucosidic Ellagitannin Family
This communication describes the first total synthesis of the 2,3,5‐O‐(S,R)‐NonaHydroxyTriPhenoylated (NHTP) and 4,6‐O‐(S)‐HexaHydroxyDiPhenoylated (HHDP) C‐glucosidic ellagitannin (−)‐vescalagin and that of its C‐1 epimer (−)‐castalagin. The key steps of these syntheses were performed and sequenced by getting inspiration from the manner through which ...
Romain Larrieu+4 more
wiley +1 more source
Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe+4 more
wiley +1 more source
Bariatric/Metabolic Surgery in Type 1 and Type 2 Diabetes Mellitus
Mufide Nuran Akcay+2 more
doaj +1 more source
Over 10 million children in the world have epilepsy, with an unknown cause in half of the cases. The gut microbiome has been associated with various neurological disorders, and certain drugs greatly disturb the microbiome. Our aim was to study the association of prenatal and childhood exposure (before the age of two) to antibiotics, proton pump ...
Unnur Gudnadottir+4 more
wiley +1 more source
Impact of Diabetes Mellitus Type 1 on Lebanese Families' Quality of Life. [PDF]
Noueiri B, Nassif N.
europepmc +1 more source
ABSTRACT Mutations in the DNA polymerase epsilon (POLE) gene are associated with an increased risk of various malignancies, including colorectal and other gastrointestinal, endometrial, ovarian, breast, and brain cancers. In extremely rare cases, POLE mutations have also been associated with pancreatic and hepatobiliary carcinomas.
Lynn Messersmith+3 more
wiley +1 more source